Comparison of 4 Acute Pulmonary Embolism Mortality Risk Scores in Patients Evaluated by Pulmonary Embolism Response Teams.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
03 08 2020
Historique:
entrez: 27 8 2020
pubmed: 28 8 2020
medline: 31 12 2020
Statut: epublish

Résumé

The risk of death from acute pulmonary embolism can range as high as 15%, depending on patient factors at initial presentation. Acute treatment decisions are largely based on an estimate of this mortality risk. To assess the performance of risk assessment scores in a modern, US cohort of patients with acute pulmonary embolism. This multicenter cohort study was conducted between October 2016 and October 2017 at 8 hospitals participating in the Pulmonary Embolism Response Team (PERT) Consortium registry. Included patients were adults who presented with acute pulmonary embolism and had sufficient information in the medical record to calculate risk scores. Data analysis was performed from March to May 2020. All-cause mortality (7- and 30-day) and associated discrimination were assessed by the area under the receiver operator curve (AUC). Among 416 patients with acute pulmonary embolism (mean [SD] age, 61.3 [17.6] years; 207 men [49.8%]), 7-day mortality in the low-risk groups ranged from 1.3% (1 patient) to 3.1% (4 patients), whereas 30-day mortality ranged from 2.6% (1 patient) to 10.2% (13 patients). Among patients in the highest-risk groups, the 7-day mortality ranged from 7.0% (18 patients) to 16.3% (7 patients), whereas 30-day mortality ranged from 14.4% (37 patients) to 26.3% (26 patients). Each of the risk stratification tools had modest discrimination for 7-day mortality (AUC range, 0.616-0.666) with slightly lower discrimination for 30-day mortality (AUC range, 0.550-0.694). These findings suggest that commonly used risk tools for acute pulmonary embolism have modest estimating ability. Future studies to develop and validate better risk assessment tools are needed.

Identifiants

pubmed: 32845326
pii: 2769827
doi: 10.1001/jamanetworkopen.2020.10779
pmc: PMC7450352
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2010779

Subventions

Organisme : NHLBI NIH HHS
ID : K08 HL128856
Pays : United States

Références

Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Med Clin (Barc). 2018 Aug 22;151(4):136-140
pubmed: 29276010
Chest. 2016 Dec;150(6):1414-1417
pubmed: 27938758
Thorax. 2014 Sep;69(9):835-42
pubmed: 24846902
Chest. 2015 Apr;147(4):1043-1062
pubmed: 25317677
Eur Respir J. 2014 Sep;44(3):694-703
pubmed: 24696111
Circulation. 2014 Jan 28;129(4):479-86
pubmed: 24226805
J Thromb Haemost. 2011 Aug;9(8):1500-7
pubmed: 21645235
Am J Respir Crit Care Med. 2005 Oct 15;172(8):1041-6
pubmed: 16020800
J Am Coll Cardiol. 2016 Mar 1;67(8):976-990
pubmed: 26916489
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
J Thromb Haemost. 2018 Jul;16(7):1313-1320
pubmed: 29733493
Arch Intern Med. 2010 Aug 9;170(15):1383-9
pubmed: 20696966
Pulm Circ. 2019 Jan 11;:2045894018824563
pubmed: 30632901
J Am Coll Cardiol. 2017 Mar 28;69(12):1536-1544
pubmed: 28335835
Thromb Haemost. 2008 Nov;100(5):747-51
pubmed: 18989514
Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k
pubmed: 25173341
Hosp Pract (1995). 2017 Aug;45(3):76-80
pubmed: 28325091
Thromb Res. 2016 Dec;148:1-8
pubmed: 27764729
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
J Thromb Thrombolysis. 2019 Jul;48(1):149-157
pubmed: 30729377
BMJ Open. 2016 Apr 29;6(4):e010324
pubmed: 27130162

Auteurs

Geoffrey D Barnes (GD)

Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan, Ann Arbor.

Alona Muzikansky (A)

Biostatistics Center, Massachusetts General Hospital, Boston.

Scott Cameron (S)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Jay Giri (J)

Department of Internal Medicine, University of Pennsylvania, Philadelphia.

Gustavo A Heresi (GA)

Department of Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, Ohio.

Wissam Jaber (W)

Division of Cardiology, Department of Internal Medicine, Emory University, Atlanta, Georgia.

Todd Wood (T)

Division of Cardiology, Department of Internal Medicine, Lancaster General Hospital, Lancaster, Pennsylvania.

Thomas M Todoran (TM)

Division of Cardiovascular Medicine, Department of Internal Medicine, Medical University of South Carolina, Charleston.

D Mark Courtney (DM)

Department of Emergency Medicine, University of Texas Southwestern, Dallas.

Victor Tapson (V)

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Cedars-Sinai Hospital, Los Angeles, California.

Christopher Kabrhel (C)

Department of Emergency Medicine, Massachusetts General Hospital, Boston.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH